Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.

ABSTRACT:

Background

Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited.

Design, setting, participants, & measurements

In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8).

SUBMITTER: Isakova T 

PROVIDER: S-EPMC3675851 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature